The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Abstract
Antibody antagonists of the insulinotropic receptor GIPR prevent weight gain in obese animal models, and the effect is enhanced by GLP-1R agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [146]
In the citing paper
“agonists and antagonists of the GIP receptor (GIPR) are currently in development, both of which have paradoxically demonstrated the ability to potentiate the weight reduction of GLP-1R agonists in preclinical models [[32], [33], [34], [35], [36], [37]]”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [33]
In the citing paper
“Neutralizing GIPR antibodies, which are presumably sequestered to the periphery, reduce body weight in an independent manner to food intake and modify energetic substrate utilization in vivo [33]”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [33]
In the citing paper
“The combination of an anti-GIPR monoclonal antibody (mAb) and a GLP-1RA has been shown to mediate more pronounced weight loss than either agent alone in preclinical obesity models33.”
From A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings (2024) · cites this paper as [33]
In the citing paper
“However, it has been shown in animal models that GIP RAs potentiates GLP-1-induced weight loss and reduces food intake [164,165].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [165]
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,697
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.305 · Cited by 1,302
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 4×
“This finding has not been observed in GIPR KO mouse models (9, 22, 32) or in other therapies targeting the GIP/GIPR axis (31).”
BackgroundMethodResultInfluential
Cited by
Items 201–238 of 238
Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors
Hutchings, C. J., Ünsal, S., Rappas, M., Barnes, M., Waldhoer, M., Holland, B., & Culka, M. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70216 · Cited by 3
Zhang, F., Chen, W., Wang, H., Wu, D., Chen, Z., Cheng, R., Hu, J., Xie, L., Qiu, Y., Zhou, Z., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.02.006 · Cited by 3
Clinical Potential of GIP in Type 2 Diabetes and Obesity
Nauck, M. A., Gribble, F. M., Reimann, F., D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Care · doi:10.2337/dci25-0141 · Cited by 3
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Yie, J., Mou, Z., & Liu, X. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag029 · Cited by 2
“Consistent with this idea, combining a GIPR-neutralizing antibody with GLP-1R agonist such as liraglutide or dulaglutide in diet-induced obese (DIO) mice resulted in signif icant, synergistic weight loss that exceeded the additive effects of either treat-ment alone [ 59, 60].”
Self-citationLiu, Y., & Liu, X. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119717 · Cited by 1
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
Vidal, J. P. (1986) · Memoria digital de Canarias (Universidad de Las Palmas de Gran Canaria) · Cited by 3
Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies
Prajapati, S. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998256797231009062744 · Cited by 1
Incretin Analogues in Therapy of Type 2 Diabetes and Obesity
Zalunin, I. A., Asrarkulova, A. S., & Kozlov, D. G. (2021) · Biotekhnologiya · doi:10.21519/0234-2758-2021-37-3-53-64 · Cited by 1
Incretin Analogues in the Therapy of Type 2 Diabetes and Obesity
Bulushova, N. V., Zalunin, I. A., Asrarkulova, A. S., & Kozlov, D. G. (2022) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683822070031 · Cited by 1
Ligand-independent modulation of GIPR signaling by splice variantsPreprint
Hang, K., Shao, L., Zhou, Q., Zhao, F., Dai, A., Cai, X., Stevens, R. C., Yang, D., & Wang, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.24.477496 · Cited by 1
Novel incretin receptor antibodies combat weight gain
Crunkhorn, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00008-9
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
思想的飞刀:是百无一用还是百发百中——读《影响世界历史的100名著排行榜》
孔庆典 (2006) · 民主与科学
Secretion and Impact of Gut Hormones in Obesity and Diabetes
Holst, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00264-9
Müller, T. D. (2022) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-1904-5552
“Zudem deuten präklinische Studien darauf hin, dass sowohl die Aktivierung [24] wie auch die Inhibition [25, 26] des GIP Rezep - tors einen positiven Einfluss auf den Energiestoffwechsel haben.”
GLP1R Agonists and Precision Medicine: In Search of Predictive Biomarkers
Bagheri, S., Pilla, S. J., & Taylor, S. I. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae548
Manchanda, Y., Desoki, R., Gardner, E. J., Perry, J. R. B., Wainscott, D. B., Stutsman, C., Langenberg, C., Coghlan, M. P., Bhatnagar, P., Ho, J. D., et al. (2025) · medRxiv · doi:10.1101/2025.08.15.25333807
TARGETING MULTIPLE PATHWAYS WITH ONE MOLECULE: THE THERAPEUTIC VERSATILITY OF TIRZEPATIDE
Jędrzejewska-Rzezak, P., Żuczek, A., Dyndał, K., Broda, M., Żuczek, O., Urbańska, K., Szczap, I., Hawryluk, A., Marzec, K., & Mokrzycka, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3902
Editorial: The impact of GIP/GIPR on metabolic diseases: how the field is evolving
Habegger, K. M., Tomás, A., Chen, R., Harris, C., Roell, W. C., & Coşkun, T. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1710843
“Gipr deletion and pharmacological GIPR antagonism in mice provide protection from diet-induced obesity and glucose intolerance (22, 23).”
Deng, Z., Zheng, D., Son, J., Du, W. J., McKimpson, W. M., Liu, Q., & Accili, D. (2025) · Acta Physiologica · doi:10.1111/apha.70141
Deng, C.-X., Chen, Z.-M., Tang, Y.-X., Xi, Z.-X., Wang, S.-Y., Wu, H.-Y., Xu, B., & Xu, T.-C. (2026) · World Journal of Pharmacology · doi:10.5497/wjp.v15.i1.113080
Identification of key genes in recurrent pregnancy loss related to obesity
Mi, H., Zhao, L., & Guo, J. (2026) · Gynecological Endocrinology · doi:10.1080/09513590.2026.2659978
Long, Y., Xu, Z., Zhang, N., Chen, G., Chen, W., Chen, Z., Wang, A., Liang, Z., Wang, Y., Zeng, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.21.719783
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
“The combined mechanism of GLP-1R agonism and GIPR antagonism is reported to augment glycaemic control and weight loss in preclinical experimental models [90].”
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Rasmussen, R. S., Nielsen, S. W., Alstrup, L., Larsson, T. S. W., Hansen, J. K., Pedersen, R. P., Vestergaard, M. B., Haddock, B., Johannesen, H. H., Larsson, H. B. W., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06788-1 · Cited by 1
James-Okoro, P.-P., Field, J., Davies, G., Pearce, A., Al‐Sabah, S., Lim, K. N., Ladds, G., Hornigold, D. C., Gribble, F. M., & Reimann, F. (2026) · Peptides · doi:10.1016/j.peptides.2026.171507
Wang, L., Jiang, F., Yuan, S., Sun, J., Zhao, J., Zhou, S., Liang, J., Li, H., Song, P., Wang, S., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156711
“Consistent with our findings, a striking observation was made with the combination of GIPR antagonism and GLP-1R agonism, where a synergistic effect on body weight was observed, nearly doubling the weight loss induced by GLP-1R agonism alone in preclinical models [50].”
Antibody peptide conjugates as multifunctional therapeutics: Mechanisms, challenges, and prospects
Xie, F., Liu, L., Cheng, Q., Xiao, D., Zhou, X., & Li, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.07.049 · Cited by 1
“For instance, in MMP-APCs, the antibody component’s potent agonistic effect on the GIPR is a crucial part of the overall therapeutic efficacy 103 .”
Manchanda, Y., Desoki, R., Gardner, E. J., Perry, J. R. B., Wainscott, D. B., Stutsman, C., Langenberg, C., Coghlan, M. P., Bhatnagar, P., Ho, J. D., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec3372
Structural Overview of GLP-1 Analogs
van der Velden, W. J. C., Andresen, A. F., & ROSENKILDE, M. M. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101037
Future GLP-1 receptor co-agonists and their cardiac effects
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05908-3
Liu, C., Wang, Y., Liu, J., Tian, P., Liu, J., Li, M., Zhang, Z., & Zhang, P. (2026) · Peptides · doi:10.1016/j.peptides.2026.171524
Seo, Y., & Woo, J. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104843
Zhang, Z., Cui, S., Jiang, C., Teng, L., Pan, H., Dong, Z., Peng, L., Wang, B., & LIU, D. (2026) · Frontiers in Veterinary Science · doi:10.3389/fvets.2026.1988580
Metadata
- Authors
- Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., Lu, S.-C., Kurzeja, R. J. M., Sivits, G., Lin, J., Chen, Q., Wang, Z., Thibault, S. A., Abbott, C. M., Meng, T., Clavette, B., Murawsky, C. M., Foltz, I. N., Rottman, J. B., Hale, C., Véniant, M. M., & Lloyd, D. J.
- Affiliations
- Amgen (United States) (US)
- Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA.
- Amgen Research, Department of Therapeutic Discovery, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA.
- Amgen Research, Department of Therapeutic Discovery, Amgen Inc., 7990 Enterprise Street, Burnaby, BC V5A 1V7, Canada.
- Corresponding author
- Killion, Elizabeth A.
- Wang, Jinghong
- Yie, Junming
- Lloyd, David J.
- ORCID
- Killion, Elizabeth A.
- Wang, Jinghong
- Yie, Junming
- Shi, Stone D.-H.
- Bates, Darren
- Min, Xiaoshan
- Komorowski, Renee
- Deng, Liying
- Lu, Shu-Chen
- Kurzeja, Robert J. M.
- Sivits, Glenn
- Chen, Qing
- Wang, Zhulun
- Thibault, Stephen A.
- Abbott, Christina M.
- Clavette, Brandon
- Murawsky, Christopher M.
- Rottman, James B.
- Hale, Clarence
- Véniant, Murielle M.
- Lloyd, David J.
- Venue
- Science Translational Medicine
- Published
- 2018-12-19
- Volume
- 10
- Issue
- 472
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2904833368
- Cited by
- 237
- References
- 42
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 33 · 2023: 28 · 2022: 31 · 2021: 31 · 2020: 20 · 2019: 27
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen Inc
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GIP receptor antagonist, obesity, diet-induced obesity, GLP-1 receptor agonists, combination therapy, weight loss, dietary intake, respiratory exchange ratio, non-human primates, pancreatic beta cells, obesity treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Antibodies, Diet, Drug Therapy, Combination, Glucagon-Like Peptides, Feeding Behavior, Gastric Inhibitory Polypeptide, Humans, Immunoglobulin Fc Fragments, Mice, Obese, Obesity, Primates, Receptors, Gastrointestinal Hormone, Recombinant Fusion Proteins, Respiration, Weight Gain, Weight Loss, Adipocytes, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.